WOBURN, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that President and CEO Oliver Peoples, Ph.D. will present a corporate overview at the 24th Annual H.C. Wainwright Global Investment Conference on September 13, 2022 at 2:00 pm ET. The conference is being held on September 12 – 14, 2022 at the Lotte New York Palace Hotel.
A live webcast of the presentation and a replay will be available on the Investor Relations section of the Company’s website at IR Events & Presentations | Yield10 Bioscience, Inc.
About Yield10 Bioscience
Yield10 Bioscience, Inc. is an agricultural bioscience company that is using its differentiated trait gene discovery platform, the “Trait Factory”, to develop improved Camelina varieties to produce proprietary seed products, and to discover high value genetic traits for the agriculture and food industries. Our goals are to efficiently establish a high value seed products business based on developing superior varieties of Camelina for the production of feedstock oils for renewable diesel, PHA bioplastics and omega-3 (DHA+EPA) oils, and to license our yield traits to major seed companies for commercialization in major row crops, including corn, soybean and canola. Yield10 is headquartered in Woburn, MA and has an Oilseeds Center of Excellence in Saskatoon, Canada.
For more information about the company, please visit www.yield10bio.com, or follow the Company on Twitter, Facebook and LinkedIn.
(YTEN-G)
Contacts:
Yield10 Bioscience:
Lynne H. Brum, (617) 682-4693, LBrum@yield10bio.com
Investor Relations:
Bret Shapiro, (561) 479-8566, brets@coreir.com
Managing Director, CORE IR
Media Inquiries:
Eric Fischgrund, eric@fischtankpr.com
FischTank PR
Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the…
Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic…
Annamycin delivering better performance 7th line than would be expected even in 2nd line for…
Glucotrack to present on next-generation continuous blood glucose monitoring technology in Innovation Hub Poster presentation…
Supports late-stage development and scalable manufacturing for LP-310, a non-steroidal oral rinse therapy for Oral…
LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a…